Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.

Epilepsy research - 1 Aug 2014

Inoue Kazuyuki, Suzuki Eri, Takahashi Toshiki, Yamamoto Yoshiaki, Yazawa Rei, Takahashi Yukitoshi, Imai Katsumi, Miyakawa Kou, Inoue Yushi, Tsuji Daiki, Hayashi Hideki, Itoh Kunihiko

Abstract excerpt

Valproic acid, which is widely used to treat various types of epilepsy, may cause severe hyperammonemia. However, the mechanism responsible for this side effect is not readily apparent. Polymorphisms in the genes encoding carbamoyl-phosphate synthase 1 (CPS1) and N-acetylglutamate synthase (NAGS) were recently reported to be risk factors for the development of hyperammonemia during valproic acid-based therapy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ammonia
Share to Anticonvulsants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Pharmacological

Share to Epilepsy

Share to Hyperammonemia

Share to Phenytoin

Share to Valproic Acid

Source

Identifiers

PMID: 24888247
DOI: 10.1016/j.eplepsyres.2014.04.008

Genes

CPS1
NAGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.PMID 24888247Read ↗

Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia.Semantic proximity Read ↗

Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.Semantic proximity Read ↗

Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.Semantic proximity Read ↗

Perioperative exacerbation of valproic acid-associated hyperammonemia: a clinical and genetic analysis.Semantic proximity Read ↗

N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectraSemantic proximity Read ↗

Association of glutamine synthetase polymorphisms rs2296521, rs10911021 and rs12136955 with plasma ammonia concentration in valproic acid-treated Egyptian epilepsy patients.Semantic proximity Read ↗

Unfavorable clinical outcomes in patients with carbamoyl phosphate synthetase 1 deficiency.Semantic proximity Read ↗

Molecular and clinical analyses of Japanese patients with carbamoylphosphate synthetase 1 (CPS1) deficiency.Semantic proximity Read ↗

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.Semantic proximity Read ↗

Effects of SCN1A and SCN2A polymorphisms on responsiveness to valproic acid monotherapy in epileptic children.Semantic proximity Read ↗

Carbamoyl phosphate synthetase polymorphisms as a risk factor for necrotizing enterocolitis.Semantic proximity Read ↗

Influence of the glutamate-glutamine cycle on valproic acid-associated hepatotoxicity in pediatric patients with epilepsy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.